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ABSTRACT 
Aim: To develop and validate a simple, precise, accurate, and sensitive UV-visible spectrophotometric method for the simultaneous estimation 
of Etoposide (ETO) and Picroside-II (PK-II) in a bulk and pharmaceutical formulation according to the ICH guidelines.  
Methods: The absorption spectra of ETO and PK-II were carried out over the range of 200-800 nm, and absorption maxima were determined. 
Multiple calibration standards were prepared of both the drugs separately, and absorbance were recorded at respective λmax. Calibration 
curve were plotted and the linear responses were studied. Various analytical method validation parameters viz. accuracy, precision, LOD, LOQ, 
robustness and ruggedness were calculated using QC standards.  
Results: The absorption maxima of ETO and PK-II were found to be 208 nm and 265 nm respectively. Linearity range for ETO and PK-II were 
found to be 1-7 μg/ml and 1-35 μg/ml with correlation coefficient 0.999 and 0.999. The intra-day and inter-day study shows percent relative 
standard deviation in between 0.11 to 1.08 and 0.12 to 1.38. LOD and LOQ were found to be 0.1321 μg/ml and 0.4003 μg/ml for ETO whereas 
0.1616μg/ml and 0.4897μg/ml for PK-II. The total percent recovery of ETO and PK-II were found to be 99.09 and 99.68 respectively. 
Conclusion:  The simple, precise, accurate, and sensitive UV-visible spectrophotometric method for the simultaneous estimation of Etoposide 
(ETO) and Picroside-II (PK-II) in a bulk and pharmaceutical formulation was developed and validated. 
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Etoposide[Fig.1] is a semi-synthetic podophyllotoxin derived 
from the roots of Podophyllumpeltatum1.It is a well-known 
anti-cancer agent used intravenously or orally2-3. Etoposide 
when administered orally shows poor and variable 
bioavailability which ranges from 25 to 75%4-6.Several 
attempts are being made by the researchers across the globe 
to achieve consistent and improvised oral bioavailability of 
the Etoposide7-12. Recently, a plant based oral bioavailability 
enhancer has been developed for the Etoposide by the 
Department of Chemical Technology, Dr. Babasaheb 
Ambedkar Marathwada University, Aurangabad. Briefly, 
Picroside-II; [Fig. 2] a phytochemical from rhizomes of 
Picrorrhizakurroa13, when administered with Etoposide, is 
found to enhance oral bioavailability of Etoposide 
consistently by 35%14. Considering therapeutic and 
commercial importance of combination of Etoposide and 
Picroside-II, it was envisaged that development of UV-Visible 
spectrophotometric method for simultaneous estimation of 
Etoposide and Picroside-II will be worth. 
 
Figure 1: Chemical structure of Etoposide 
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Figure 2: Chemical structure of Picroside-II 
MATERIALS AND METHODS 
Chemical and Reagents 
Picroside-II (purity 98% by HPLC) was obtained as gift 
sample from Natural Products Chemistry Division of Indian 
Institute of Integrative Medicine (CSIR), Jammu. Etoposide, 
was purchased from TCI chemicals, India. Methanol 
(distilled) was used as solvent for preparation of diluents.  
Instruments Used 
A UV-visible double beam spectrophotometer with spectra 
manager software UV-530, Jasco was used for multi 
component analysis. Quartz cells having 3 cm length along 
with 1 cm path length were used for spectral measurement. 
Weighing balance (Vibra HT, Essae) with internal calibration 
mode was used for the accurate weighing. 
Preparation of standard stock solution 
The standard stock solution having concentration 1000 
μg/ml(Stock-I) of each ETO and PK-II were prepared 
separately by dissolving accurately weighed 5 mg of API in 5 
ml Methanol. Stock-I solution of both the bulk drug were 
further suitably diluted with solvent system Methanol to 
achieve the solution of concentration 100 μg/ml (Stock-II) 
and 10 μg/ml (Stock-III).Similarly, the standard stock 
solutions of combined dosage form of ETO and PK-II were 
prepared having the concentrations 1000 μg/ml, 100 μg/ml 
and 10 μg/ml. 
Determination of wavelength of maximum absorbance 
(λmax) 
The standard stock solution of ETO and PK-II having 
concentration 10µg/ml (Stock-III) were scanned separately 
in UV range from 200-800 nm against reference sample 
Methanol and spectrum were recorded. The λmax were 
determined of both bulk drug. In order to achieve accuracy 
the above process was repeated 4 times. 
Preparation of calibration curve 
Calibration curve were defined by diluting the stock-II 
standard solution of both bulk drug i.e. ETO and PK-II to 
achieve the seven different calibration standards i.e. 1, 2, 3, 4, 
5, 6, and 7 μg/ml for ETO and 1, 5, 10, 15, 20, 25, 30, and 35 
μg/ml for PK-II. Each calibration standard was scanned at 
pre-defined λmax i.e. 208 nm and 265 nm of ETO and PK-II 
respectively using fixed wavelength measurement mode. The 
absorbance at respective wavelength were noted of various 
calibration standards. The concentration vs. absorbance 
graph were plotted using Excel program of Microsoft Office 
2010separately. Above mentioned procedure was repeated 
five times to obtain reproducible results. 
 
Development of Simultaneous Equation 
To determine both drugs by the technique of simultaneous 
equation method (vierodt’s method), sample should contain 
two absorbing drugs each of which absorbs at the λmax 
different from the other [Table 1]. 
The concentration of both the can be obtained by formula - 
Cx   = (A2ay1 – A1ay2) / (ax2ay1 - ax1ay2)  
Cy   = (A1ax2– A2ax1) / (ax2ay1 - ax1ay2)  
Where, 
λ1: Wavelength maxima for ETO 
λ2: Wavelength maxima for PK-II   
ax1 and ax2: Absorptivity of ETO at 208 nm and 265 nm   
ay1 and ay2: Absorptivity of PK-II at 208 nm and 265 nm   
A1: Absorbance of ETO at 208 nm   
A2: Absorbance of PK-II at 265 nm   
CX and CY: the concentration of ETO and PK-II respectively in 
the diluted sample. 
Method Validation 
The developed UV method for the estimation of ETO and PK-
II in bulk drug and pharmaceutical formulation was validated 
as per the ICH guidelines. Various parameters like linearity 
and range, accuracy, precision, robustness, ruggedness, limit 
of detection (LOD) and limit of quantitation (LOQ) were 
analysed using pre-defined calibration standards or quality 
control standards as described below 15-16. 
Linearity and Range 
Linearity was evaluated by linear regression analysis and 
calculated by least square method. The calibration curves 
shows correlation between absorbance and concentration 
level within the concentration range of 1-7 μg/ml for ETO 
and 1-35μg/ml for PK-II.  Plots were subjected to linear 
regression least square analysis. R square value was 
important factor for establishing linearity. The interval 
between upper and lower concentration limit with 
acceptable linearity was reported to be the range of the 
proposed UV method. 
Accuracy 
The accuracy was determined by means of recovery studies 
by evaluating % mean recovery of both the drugs. The 
known concentrations of drug were added at the different 
level viz. 80%, 100%, and 120% level. The pentaplicate of 
three different pre-defined concentration solution of both 
the drugs i.e. ETO (1.2, 3.4, and 6.8 µg/ml) and PK-II (1, 20, 
and 35 µg/ml) were prepared. The absorbance was 
measured at wavelength 208 nm and 265 nm wavelength for 
ETO and PK-II respectively. The above method was perform 
three times. 
The percent recovery was calculated by formula - 
%RC= (SPS-S/SP) × 100 
Where, 
SPS = Amount found in the spiked sample 
S = Amount found in the sample 
SP = Amount added to the sample 
% RC = Percent recovery 
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Precision 
The repeatability of method was checked by statistical 
evaluation. Intraday and inter-day variations were studied. 
Five different solution of both the drug were prepared for 
ETO (1.2, 3.4, and 6.8 µg/ml) and PK-II (1, 20, and 35 µg/ml) 
and analysed at morning, afternoon and evening time of 
three consecutive days. Deviation in the results was 
calculated in terms of % RSD (% relative standard deviation).  
Robustness 
Robustness was determined by changing the wavelength 
±1nm from 208nm for ETO and 265nm for PK-II. Middle 
level quality control sample of ETO (3.4 µg/ml) and PK-II 
(20µg/ml) was prepared and analyzed at pre-defined 
wavelength. The results were calculated in terms of % RSD. 
Ruggedness 
Ruggedness study of the method was carried out by 
analyzing triplicate samples of ETO (3.4 µg/ml) and PK-II (20 
µg/ml) using two different instruments (V-530, Jasco and 
BA-UV-2600, Bioage). Results were expressed in terms of % 
RSD. 
Limit of Detection (LOD) 




SD= Standard deviation of Y-intercepts 
S= Slope of calibration curve  
Limit of Quantitation (LOQ) 




SD= Standard deviation of Y-intercepts 
S= Slope of calibration curve 
Estimation of ETO and PK-II content in pharmaceutical 
formulation 
In-house formulation of ETO was prepared by using bio 
enhancer PK-II with pharmaceutically accepted excipients. 
The formulation contain ETO and PK-II in ratio 
of2:1.Weighed the quantity of powder equivalent to 2 mg of 
ETO and 1mg of PK-II and dissolved in 1 ml of methanol 
using ultra sonication and the solution was filtered using 
0.22 µm filter. Filtered solution was suitably diluted to get 
concentration in ratio 2:1 (ETO: PK-II) and analyzed for drug 
content using simultaneous equation method. 
RESULTS AND DISCUSSION 
Determination of wavelength of maximum absorbance 
(λmax) 
Identification of maximum absorbance wavelength is 
prerequisite for quantitative UV analysis. Solution with 
absorbance value less than 1 were considered to be 
appropriate for the determination of wavelength having 
maximum absorbance. Considering the above mentioned 
point determination of λmax of ETO and PK-II solution of 10 
µg/ml concentration each were carried out by full scan mode 
of UV-Visible spectrophotometer. The full scan mode was 
processed by Jasco UV software and λmax were determined. 
The λmax was found to be 208nm and 265nm for ETO and 
PK-II [Fig. 3 and Fig. 4]respectively. The overlain spectra of 
both drugs shown in Fig. 5.   
 
Figure 3: UV-Spectrum of ETO 
 
Figure 4: UV-Spectrum of PK-II 
 
Figure 5: Overlap spectra of ETO and PK-II 
 
Preparation of calibration curve 
Quantification of unknown samples by UV-Visible 
spectrophotometer or any other instrumental method of 
analysis requires reproducible calibration curve and a 
mathematical equation representing correlation between 
concentration and the response. Considering the utility of 
quantitative analysis of ETO and PK-II, calibration curve for 
both drug were developed using seven different calibration 
standards. The absorbance of different calibration standards 
at wavelength 208 nm and 265 nm for ETO and PK-II 
respectively were recorded by fixed wavelength mode. 
Calibration curve was repeated five times. 
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Method validation 
Linearity and Range 
Linearity and range are the key parameters of analytical 
method which demonstrates the limit within the intended 
method to be used for its optimum performance. Considering 
the importance of linearity and the range, seven points 
calibration curve of ETO between the range 1-7 μg/ml and 
PK-II between the range 1-35 μg/ml were plotted. The 
concentrations and the respective mean absorbance values 
of ETO and PK-II are mentioned in Table 1. Calibration curve 
were subjected to least square regression analysis yielded an 
equation; y = 0.1238X + 0.0034 and y = 0.0252x + 
0.0059with correlation coefficient and for ETO and PK-II 
respectively [Fig. 6 and Fig. 7]. The linearity study revealed 
that the developed UV method was found to be linear 
adherence to the system of Beers Law over the concentration 
range of 1 to 7 µg/ml for ETO and 1 to 35 µg/ml for PK-II. 
 
Table 1 – Linearity study for ETO and PK-II 
Sr. No. Conc. 
(µg/ml) 




Absorbance of PK-II at 
265 nm 
1 1 0.1302 1 0.0335 
2 2 0.2505 5 0.1326 
3 3 0.3803 10 0.2618 
4 4 0.4893 20 0.5168 
5 5 0.6219 25 0.6344 
6 6 0.7378 30 0.757 
7 7 0.8802 35 0.8911 
 
 
Figure 6.Calibration curve for ETO 
 
Figure 7. Calibration curve for PK-II
 
Accuracy 
Accuracy is the measure of closeness of the experimental 
value to the actual amount of the substance in the matrix. 
Accuracy is to be established over the entire calibration 
range of the analytical method so that at any point of 
determination, results obtained would be reliable.  UV 
method for ETO and PK-II, accuracy was established by 
recovery studies. Mean recovery of ETO was found to be 
100.09, 98.12, and 99.06 and of PK-II was found to be 100.15, 
98.32, and 100.59 at 80 %, 100% and 120% standard 
addition respectively. % RSD were found to be less than 2for 
the ETO and PK-II, recovery studies are shown in Table 2. 
The results of accuracy studies, determined that the 
developed UV method is highly accurate as the percent 
recovery was found to be between 97 to 100%.  
 




















1.2 80 100.09 0.18 1 80 100.15 0.98 
3.4 100 98.12 1.90 20 100 98.32 0.14 
6.8 120 99.06 1.85 35 120 100.59 1.77 
 
Precision 
Precision is a measure of degree of scatter, expresses the 
reproducibility of the measurements. It is expected that an 
analytical method should generate reproducible outcomes. 
Precise analytical method leads to accurate results. 
Considering the importance of reproducible and accurate 
results, intra-day and inter-day precision of developed UV 
method were established at 1.2, 3.4 and 6.8 μg/ml 
concentration levels of ETO and at 1, 20, and 35μg/ml 
concentration levels of PK-II. The results were expressed in 
terms of mean absorbance values, percent assay and % RSD 
for the intra-day and inter-day precision study, 
demonstrated in Table 3 and Table 4respectively for ETO 
and PK-II. Percentage RSD values of intra-day precision 
y = 0.1238x + 0.0034 















Conc μg/ml  
Calibration of ETO y = 0.0252x + 0.0059 












Conc μg/ml     
Calibration Curve of PK-II 
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study were found to be between 0.23 and 0.70 for ETO and 
between 0.11 and 1.08 for PK-II whereas those of inter-day 
precision study were between 0.24 and1.05 for ETO and 
between 0.17 and 1.38 for PK-II. % RSD values were less 
than 2, demonstrated the precision of developed UV method. 
 






Mean % Assay % RSD Mean % Assay % RSD 
1.2 0.1556 99.76 0.70 1 0.0264 100.30 1.08 
3.4 0.4437 100.39 0.25 20 0.5331 99.62 0.13 
6.8 0.8718 98.62 0.23 35 0.9321 100.95 0.11 
 






Mean % Assay % RSD  Mean % Assay % RSD 
1.2 0.1558 99.87 1.05 1 0.0264 100.17 1.38 
3.4 0.4410 99.77 0.62 20 0.5336 100.17 0.12 




Robustness is the ability of a method to resist the change in 
its performance in spite of small un-intentional change in 
method parameters like solvent composition, buffer 
strength, pH, ±1nm wavelength etc. Change may occur and 
hamper the performance, it is expected that such change 
should not alter the performance of the analytical method. 
Hence, robust analytical method is studied. Robustness of 
proposed UV method was established by scanning the 
sample solution for ±1nm wavelength from 208 nm for ETO 
and 265 nm for PK-II. Change in the wavelength by ±1nm did 
not affect the performance of developed method. The% RSD 
values were found to be between 0.88 and 1.48 for ETO and 
between 0.15 and 0.23for PK-II, shown in Table 5for ETO 
and PK-II respectively. Percentage RSD values were below 2 
depict that the proposed UV method was robust in nature. 
 






λmax Absorbance % RSD λmax Absorbance % RSD 
3.4 207 0.4379 0.8810 20 264 0.5169 0.233 
3.4 209 0.4359 1.4876 20 266 0.5213 0.153 
 
Ruggedness 
Ruggedness is the ability to resist the change in method 
performance in-spite of influential environmental factors 
like temperature, pressure, equipment, etc. Rugged 
analytical methods are free from environmental/external 
factors impact. The ruggedness of proposed UV method, for 
ETO and PK-II solutions were analysed by using two 
different UV-Visible spectrophotometers belongs to different 
laboratories. Sample analysis resulted into % RSD values 
between 0.63 and 1.81 for ETO and between 0.23 and 0.30 
for PK-II. Results showed that the proposed UV method was 
rugged as % RSD values were less than 2, shown in Table 6 
of ETO and PK-II. 
 
 






Instrument Absorbance % RSD Instrument Absorbance %RSD 
3.4 Jasco 0.4383 0.63 20 Jasco 0.5169 0.23 
3.4 Bioage 0.4467 1.81 20 Bioage 0.5110 0.30 
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Limit of Quantitation (LOQ) and Limit of Detection (LOD) 
Generally, LOQ is the first calibration standard. LOQ 
represents the lowermost concentration that can be 
analysed. LOD represents the lowest quantity of substance 
that can be distinguished from the absence of that substance 
(a blank value) with a stated confidence level (generally 
99%). LOD and LOQ of proposed UV method were found to 
be 0.1321 and 0.4003µg/ml for ETO whereas 0.1616 and 
0.4897 µg/ml for PK-II, as shown in Table 7 for ETO and PK-
II. Lower LOQ values indicated that the proposed method 
would be sensitive enough to quantify the ETO and PK-II 
content of samples at its lower level. 
Table 7 – LOD and LOQ for ETO and PK-II 
Sr. No. Parameter ETO PK-II 
1 LOD 0.1321μg/ml 0.1616μg/ml 
2 LOQ 0.4003 μg/ml 0.4897μg/ml 
 
Estimation of Etoposide and Picroside-II content in 
pharmaceutical formulation 
The developed UV method was successfully applied for 
estimation of ETO and PK-II content in pharmaceutical 
formulation. The ETO and PK-II content in the 
pharmaceutical formulation was found to be 101.36% and 
100.91% respectively by simultaneous equation method. 
CONCLUSION 
The simple, precise, accurate, and sensitive UV- visible 
spectrophotometric method for the simultaneous estimation 
of ETO and PK-II in a bulk and pharmaceutical formulation 
was developed and validated. The recovery result confirms 
the accuracy of method. The proposed method was found to 
be robust and rugged in nature. Thus, it can be effectively 
applied for the estimation of ETO and PK-II in bulk and 
pharmaceutical formulation. 
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